It has been 50 years since the first patients with tardive dyskinesia (TD) were described, but
the pathophysiology is only partially understood and effective treatments have remained …

Tardive dyskinesia (TD) is a persistent hyperkinetic movement disorder associated with
dopamine receptor blocking agents including antipsychotic medications. Although …

The pathophysiology of TD is still not clear, and the traditional dopamine (DA)
hypersensitivity model seems inadequate. Animal experiments suggest that blockade of …

Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum Page 1
Neuronal traffic signals in tardive dyskinesia: not enough “stop” in the motor striatum Stephen …

Tardive dyskinesia is a serious, disabling and potentially permanent, neurological
hyperkinetic movement disorder that occurs after months or years of taking psychotropic …

Tardive dyskinesia (TD) encompasses the spectrum of iatrogenic hyperkinetic movement
disorders following exposure to dopamine receptor-blocking agents (DRBAs). Despite the …

Tardive dyskinesia (TD) is a syndrome of abnormal involuntary movements that follows
treatment with dopamine D2-receptor antagonists. Recent approval of vesicular monoamine …

Tardive dyskinesia (TD) is a serious, often disabling, movement disorder that is caused by
medications that block dopamine receptors (ie, neuroleptics, anti-emetics). There is currently …

Tardive dyskinesia (TD) is a potentially permanent movement disorder resulting from chronic
use of dopamine receptor blocking agents (DRBA). Identified risk factors include the type of …

Introduction Chronic treatment with dopamine D2 receptor antagonists has been proposed
to lead to dopamine receptor supersensitivity. Frequently, this is conceptualized as …